We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Comprehensive Liquid Biopsy Guides Metastatic Cancer Treatment

By LabMedica International staff writers
Posted on 21 Jun 2016
Print article
Image: The Guardant360 kit for biopsy-free tissue sequencing for cancer (Photo courtesy of Guardant Health).
Image: The Guardant360 kit for biopsy-free tissue sequencing for cancer (Photo courtesy of Guardant Health).
Liquid biopsies offer a promising approach for identifying druggable genomic alterations, which is the ability of a portion of a genome to be targeted by a drug, especially by a small molecule drug, without the need for costly and invasive tissue biopsies.

The results of the first prospective clinical trial using a comprehensive liquid biopsy test as the sole diagnostic tool used by doctors to guide metastatic cancer patients to matched therapy across multiple cancers has been recently announced.

Scientists at the Samsung Medical Center (Sungkyunkwan University School of Medicine, Seoul, Korea) and a commercial company collaborated in the first prospective study to evaluate the response of advanced cancer patients to matched therapy based on circulating tumor DNA (ctDNA)-detected alterations across different solid tumor cancers without tissue biopsies available for molecular testing. The study of 200 patients demonstrated high actionability in matching patients to targeted therapies, as well as statistically significant response rates in lung (88%) and gastric (60%) cancers.

The study used Guardant360 (Guardant Health, Inc, Redwood city, CA, USA), the first and only comprehensive liquid biopsy that covers all guideline recommended biomarkers in a single test. Guardant360 is a biopsy‐free, simple blood test for tumor genomic profiling. It takes 14 days or less from the time it is received at the laboratory for a full report to reach the ordering doctor. This is two full weeks sooner than with a tissue sample from a best in class cancer center. The Guardant360 blood test also provides samples with an adequate level of cell free DNA to test 99.8% of the time. In contrast, the samples used for tissue sequencing typically have insufficient DNA from 20% to 40% of the time. This adds further delays as either a new sample from the original tumor block must be present or another biopsy must be done to get enough tissue to test.

Jeeyun Lee, MD, the primary investigator on the study, said, “The genomic landscape of variants we found with Guardant360 were comparable to what we saw in a tissue-based prospective clinical utility study. When these patients are then guided to matched therapy based on ctDNA profiling, the response rate was again comparable to what we see when selection is based on tumor specimens. This blood-based technology also overcomes tumor heterogeneity by providing a more global summary of all the aberrations in different metastatic sites. It also may reduce harm to patients by obviating the need for invasive biopsy. The study was presented on June 6, 2016, at the American Society of Clinical Oncology Annual Meeting held in Chicago, IL, USA.

Related Links:
Samsung Medical Center
Guardant Health
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.